Therapeutics Company Announces Supply Agreement With Pharmaceutical Giant: Merck
Pioneering a New Era in Cancer Treatment: CytomX and Merck's Strategic Collaboration on CX-801.
Striding towards revolutionizing cancer therapy, CytomX Therapeutics, Inc. (Nasdaq: CTMX) has announced a clinical trial collaboration and supply agreement with pharmaceutical giant Merck (known as MSD outside of the US and Canada). This collaboration is set to explore the therapeutic potential of CX-801, a novel, dually-masked interferon-alpha2b (IFNα2b) cytokine, in combination with Merck’s acclaimed anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The focus is on patients with advanced metastatic solid tumors, including melanoma, renal cell carcinoma, and head and neck squamous cell carcinoma, marking a pivotal moment in the fight against cancer. $CytomX (CTMX.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
买跌不追涨 : But why did it plummet? This news should have skyrocketed, ah, performance has improved
赌徒 买跌不追涨 : Fall first, then rise
买跌不追涨 赌徒 : Hope, I'm following